|Bid||97.9900 x 100|
|Ask||98.0200 x 100|
|Day's Range||95.52 - 104.46|
|52 Week Range||63.12 - 125.86|
|PE Ratio (TTM)||29.52|
|Forward Dividend & Yield||3.84 (3.41%)|
|1y Target Est||N/A|
Stocks are falling sharply and bond prices are climbing after the Trump administration moved to place tariffs on some goods imported from China and restrict Chinese investment. The Chinese government said ...
Investors were hoping for accelerated approval so the drug could quickly begin bringing in revenue. But the new trial results also undermine the core reasons AbbVie bought Stemcentrx and Rova-T in the ...
Among the things everybody knows, but that everyone frequently forgets: don't trust messiah's who think they can improve your odds in drug discovery. Today's lesson? Rova-T, being developed by AbbVie.
Shares of pharmaceutical behemoth AbbVie Inc. (ABBV) dropped more than 11% in early morning trading Thursday after the company???s Rova-T program reported disappointing mid-stage results.
AbbVie Inc's experimental lung cancer drug data was not effective enough to seek a faster approval, in a setback to the company's efforts to build its cancer drug pipeline and cut dependence on its blockbuster Humira. AbbVie has been building a portfolio of oncology drugs to counter competitive threats to its rheumatoid arthritis treatment, Humira, which accounts for about two-thirds of its overall sales.
AbbVie tanked more than 10% early Thursday after scuttling plans to seek accelerated approval for a lung cancer drug.